World Congress on Biosensors 2014

World Congress on Biosensors 2014
Biosensors 2014

Monday, 27 June 2011

Optibrium Announces Free Models to Predict Toxicity of Compounds

Optibrium™, a provider of software solutions for drug discovery, announces the availability of a range of models to help predict the toxicity of potential new compounds. Optibrium has generated a range of Quantitative Structure Activity Relationship (QSAR) models of key toxicity endpoints, based on data made available by the US Environmental Protection Agency (EPA) as part of its Toxicity Evaluation Software Toolkit (T.E.S.T.). The toxicity prediction models were built with the Auto-Modeller™ module of the newly launched StarDrop™ 5 and are available to all StarDrop users free-of-charge. To find out more and download the models please visit Optibrium’s on-line community at http://www.optibrium.com/community.

Whether compounds are intended as drugs, cosmetics, agrochemicals or for other industrial applications, it is essential to understand their potential to cause toxic effects. Understanding this can allow scientists to prioritise chemical structures for further research or identify the most appropriate downstream experiments to confirm their safety. However, the ability to predict toxicities in compounds can be extremely challenging. Models have a high degree of uncertainty in the predictions they make due to the complexity and variety of chemical and biological mechanisms that lead to toxicities.

StarDrop, from Optibrium, is an interactive platform that guides scientists to make decisions on the design and selection of high quality compounds with the aim of achieving an optimal balance of properties.  StarDrop provides an ideal environment for application of toxicity models to the selection of compounds. Its probabilistic scoring algorithm allows predictive models of toxicity to be used, while explicitly taking into consideration the uncertainty in each prediction.  This ensures that uncertain predictions are not given undue weight, relative to other data, when prioritising compounds that are more likely to have an appropriate balance of properties. As a result, compounds which are more likely to be toxic are efficiently identified, improving lead optimisation. The unique Glowing Molecule™ feature within StarDrop offers an innovative visualisation that highlights regions of a compound with a significant influence on a predicted property. As a result, this provides a link between the predicted toxicity and the chemical mechanism and guides users in the redesign of compounds with improved safety.

“These predictive toxicity models complement the range of properties that can already be predicted with StarDrop’s ADME QSAR module. As they’re based on public-domain data sets, we’re pleased to offer them free-of-charge to all of our users.” comments Dr. Matthew Segall, CEO of Optibrium. “Many of the toxicity prediction models developed with the use of StarDrop are particularly relevant to potential environmental pollutants. This illustrates the usability of StarDrop not just for drug discovery applications, but for industrial, agrochemical or cosmetic applications.”

The toxicity prediction models conform to the Organisation for Economic Cooperation and Development (OECD) principles for validation of QSAR models for regulatory purposes and have also been found to perform equivalently or better than the EPA T.E.S.T. models on the same validation sets. All models were built automatically with StarDrop’s Auto-modeller module, illustrating that the Auto-Modeller is capable of building models that compare favourably with those created with more ‘manual’ methods. For further information please visit Optibrium’s on-line community at http://www.optibrium.com/community.

Friday, 24 June 2011

Just Published: Biosensors & Bioelectronics

A new issue of this journal has just been published. To see abstracts of the papers it contains (with links through to the full papers) click here:
Selected papers from the latest issue:

Femtomolar DNA detection by parallel colorimetric darkfield microscopy of functionalized gold nanoparticles

23 June 2011, 22:23:56Go to full article
Publication year: 2011
Source: Biosensors and Bioelectronics, In Press, Accepted Manuscript, Available online 23 June 2011
Remco, Verdoold , Ron, Gill , Felicia, Ungureanu , Robert, Molenaar , Rob P.H., Kooyman
We introduce a sensing platform for specific detection of DNA based on the formation of gold nanoparticles dimers on a surface. The specific coupling of a second gold nanoparticle to a surface bound nanoparticle by DNA hybridization results in a red shift of the nanoparticle plasmon peak. This shift can be detected as a color change in the darkfield image of the gold nanoparticles. Parallel detection of hundreds of gold nanoparticles with a calibrated true color camera enabled us to detect specific binding of target DNA. This enables a limit of detection below 1.0×10−14M without the need for a spectrometer...

Controlled immobilization of acetylcholinesterase on improved hydrophobic gold nanoparticle/prussian blue modified surface for ultra-trace organophosphate pesticide detection

23 June 2011, 22:23:56Go to full article
Publication year: 2011
Source: Biosensors and Bioelectronics, In Press, Accepted Manuscript, Available online 23 June 2011
Shuo, Wu , Xiaoqin, Lan , Wei, Zhao , Yupeng, Li , Lihui, Zhang , ...
An ultrasensitive amperometric acetylcholinesterase (AChE) biosensor was fabricated by controlled immobilization of AChE on gold nanoparticles/poly(dimethyldiallylammonium chloride) protected Prussian blue (Au-PDDA-PB) nanocomposite modified electrode surface for the detection of organophorous pesticide. The Au-PDDA-PB membrane served as an excellent matrix for the immobilization of enzyme, which not only enhanced electron transfer but also possessed a relatively large surface area. In addition, the surface hydrophilicity of the Au-PDDA-PB nanocomposite was finely controlled in the static water contact angle range of 25.6 to 78.1° by adjusting the ratio of gold nanoparticles to PDDA-PB. On an optimized hydrophobic surface, the AChE adopts an orientation...

Fast Dynamic Array™ IFC for Ag-Bio & Genotyping Studies

Fluidigm Corporation has introduced its 192.24 Dynamic Array™ IFC, designed to genotype 192 samples against 24 SNP assays in a single run, providing 4,608 data points in just one hour. The 192.24 integrated fluidic circuit (IFC) has immediate applicability in agricultural biotechnology and genome wide association studies.

Fluidigm's latest integrated fluidic circuit features an innovative design that greatly increases sample throughput for common SNP genotyping applications. Using the new Fluidigm IFC Controller RX, the new Dynamic Array IFC enables sample loading within 30 minutes, and thermal cycling in another 30 minutes, resulting in a greatly accelerated workflow. The power to deliver 4,608 data points in one hour makes the Fluidigm system the fastest commercially practical genotyping solution in the industry today. The 192.24 Dynamic Array chip addresses the high throughput needs of genotyping by providing a four-fold increase in sample throughput when compared to the 48.48 Dynamic Array IFC.

This accelerated workflow and increased throughput enables more data points, while the 192.24 chip retains Fluidigm's 99.75 percent or greater call accuracy and 99 percent or greater call rates. The new chip can be read using either the BioMark™ HD or EP1™ Systems.

"The Fluidigm 192.24 Dynamic Array chip enables life science researchers to achieve ultra-low cost, and rapid throughput while maintaining full assay and reagent flexibility. Providing the ability to use fewer SNP assays, and run a high number of samples is a format that is ideal for some applications in Ag-Bio and for GWAS follow-up studies," said Gajus Worthington, Fluidigm president and chief executive officer.

The 192.24 is particularly suited to take advantage of Fluidigm's new SNPtype™ Assays for genotyping. While the 192.24 Dynamic Array chip will support all industry-standard assays, SNPtype Assays offer a low-cost SNP genotyping solution, are made on-demand, and are ready to meet high-throughput needs for a wide range of agricultural applications and confirmation of next-generation sequencing results.

Fluidigm IFCs, including the 192.24 chip, use just microliters of materials, allowing scientists to achieve comprehensive genetic profiling from miniscule amounts of sample. Each reaction chamber in the 192.24 chip requires only eight nanoliters of material. In addition, all Fluidigm Dynamic Array IFCs feature a matrix-style architecture that automatically assembles every possible reaction between the samples and the assays providing up to 99 percent fewer pipetting steps than needed when using 384-well plates.

Fluidigm (NASDAQ:FLDM) develops, manufactures and markets microfluidic systems for growth markets in the life science and agricultural biotechnology, or Ag-Bio, industries. Fluidigm's proprietary microfluidic systems consist of instruments and consumables, including integrated fluidic circuits, or chips, and reagents. These systems are designed to significantly simplify experimental workflow, increase throughput and reduce costs, while providing the excellent data quality demanded by customers. Fluidigm actively markets three microfluidic systems including nine different commercial chips to leading pharmaceutical and biotechnology companies, academic institutions and Ag-Bio companies.

For more information, please visit
www.fluidigm.com.

SAGE-N RESEARCH SORCERER PLATFORM IMPLEMENTED BY THE

Sage-N Research, Inc., the world leader in supplying Integrated Data Appliances (IDAs) for proteomics research, announced that the State University of New York at Buffalo’s pharmaceutical sciences research group has chosen the Sage-N Research SORCERERTM platform to assist with its advanced proteomics research.

One of the primary reasons for this was to take advantage of the sophisticated algorithms and server capabilities that the SORCERER offers, as an overall life science platform. The SORCERER will replace the current super-computers that are used within the University’s laboratory to characterize and identify proteins and handle the large amounts of data generated from high throughput mass spectrometers.

The Lab of Clinical Proteomics and Pharmaceutical Analysis, led by Dr. Jun Qu, Assistant Professor at The State University of New York at Buffalo and the Chief Scientist in Bioanalysis in CEBLS, has decided to go with Sage-N Research’s SEQUEST® 3G search engine and Matrix Science’s Mascot®, both hosted on the SORCERER platform, to study a variety of applications including diagnostics and biomarker discovery for cardiovascular diseases, colon, pancreatic and prostate cancer, cocaine addiction, retina degeneration, COPD and HIV.

The SORCERER from Sage-N Research is a “plug and play” appliance for life sciences designed to support multiple software programs and is well suited to researchers in high-throughput laboratories, core facilities and corporate environments. It provides a unique combination of optimized hardware and can be easily customized with different post-processing tools to suit an individual customer’s needs. The platform also offers high-level server-based solutions for storage, back-up and rapid processing of the complex data-sets generated by high end mass spectrometers.

The University at Buffalo selected SORCERER to be used with both Mascot and SEQUEST 3G, to optimize the search conditions. This solution has replaced the super-computer in the University at Buffalo’s laboratory, as it offers the capability to handle the vast amounts (up to a terabyte) of information generated by a unique long-gradient nano-Lliquid Chromatography Mass Spectrometry (nano-LC/MS) developed in Qu’s lab.

“It has been great to be able to finally deploy both Mascot and SEQUEST 3G on the Sage-N Research SORCERER platform and experience the benefits of two very powerful search engines for important protein ID applications,” commented Dr. Jun Qu. “Most members of the industry are still using standalone PC servers which can be time consuming to configure and would consume more power to process the same amount of data. For example, 60k-80k spectra were generated by a single nano-LC/MS run of a clinical sample; in our lab, one typical clinical project will involve the analysis of 2-3 millions of spectra, which is a heavy burden even for a super computer.  We have found the SORCERER platform to be very reliable, easy-to-use and the next generation of Information Technology for life sciences.” In addition, John Cottrell, Director at Matrix Science comments “We are excited that the University at Buffalo has chosen to harness the power of Mascot on the SORCERER platform for its advanced proteomics research. This solution allows users to handle large amounts of data easily and efficiently, accelerating their vital research programs.”

For more information about Sage-N Research, Inc. and its easy-to-use proteomic data analysis solution, please visit www.sagenresearch.com or e-mail info@SageNResearch.com.

SORCERERTM is a trademark of Sage-N Research, Inc.
SEQUEST® is registered trademark with the University of Washington
Mascot® is a registered trademark of Matrix Science Ltd

High Sensitivity Dynamic Light Scattering System

The W130i from Avid Nano is a breakthrough, high sensitivity dynamic light scattering system for size and molecular weight measurement of proteins, biomolecules and nanoparticles. 

Engineered to meet the demands of today's research laboratories, the W130i dynamic light scattering system delivers outstanding performance from only 5µl of sample in seconds. The W130i combines ultimate measurement performance with an economical benchtop footprint, rugged durability and supreme user convenience. 

Critical to the W130i's outstanding performance is the integration of Avid Nano's unique SABRe - Stabilized Anti-Back Reflection optical design.  The result is an optimised measurement performance, immune to reflections and permanently mechanically stable. The patent-pending 5?l BladeCell cuvette combines the ultimate convenience of a disposable sample holder with the measurement quality of a quartz cuvette.  Built-in compatibility with standard fluorescence cuvettes and flow cells make the W130i a uniquely versatile instrument. With decades of experience in DLS design and manufacture, Avid Nano has built unrivalled reliability into the W130i.  Every component has been designed for superior performance, reliability and low maintenance operation. The W130i is also amazingly small, occupying the very minimum of valuable laboratory bench space.

Dynamic light scattering is a non-invasive technique that enables quick and accurate measurement of hydrodynamic radius, size distribution, estimated molecular weight and aggregate content of biomolecules and nanoparticles in solution or suspension.  Avid Nano DLS systems find particular utility in applications including crystal screening, buffer optimisation, solubility screening, aggregate detection, micelle formation, engineered nanoparticles and formulation development.

Operating from its UK headquarters - Avid Nano is building a strong reputation for its technical expertise, applications support and delivering DLS systems that reliably deliver top quality results.  For further information on the W130i please visit www.avidnano.com/downloads/downloads.htm or contact Avid Nano on +44-1494-614659 or email info@avidnano.com.

Wednesday, 22 June 2011

2nd International Conference on Bio-Sensing Technology 2011

Amsterdam, The Netherlands
Register by 12th August 2011 and go into a raffle for a FREE Delegate Pass or one of five tickets to the world-famous Van Gogh Museum.

Just Published: Journal of Chromatography B

A new issue of this journal has just been published. To see abstracts of the papers it contains (with links through to the full papers) click here:
Selected papers from  this issue:

Computational investigation of the substrate recognition mechanism of protein d-aspartyl (l-isoaspartyl) O-methyltransferase by docking and molecular dynamics simulation studies and application to interpret size exclusion chromatography data

21 June 2011, 21:42:29Go to full article
Publication year: 2011
Source: Journal of Chromatography B, In Press, Accepted Manuscript, Available online 21 June 2011
Ikuhiko, Noji , Akifumi, Oda , Kana, Kobayashi , Ohgi, Takahashi
Unusual amino acid residues such as l-β-aspartyl (Asp), d-α-Asp, and d-β-Asp have been detected in proteins and peptides such as α-crystallin in the lens and β-amyloid in the brain. These residues increase with age, and hence they are associated with age-related diseases. The enzyme protein d-aspartyl (l-isoaspartyl) O-methyltransferase (PIMT) can revert these residues back to the normal l-α-Asp residue. PIMT catalyzes transmethylation of S-adenosylmethionine to l-β-Asp and d-α-Asp residues in proteins and peptides. In this work, the substrate recognition mechanism of PIMT was investigated using docking and molecular dynamics simulation studies. It was shown that the hydrogen bonds of Ser60...

Application of hollow fiber liquid phase microextraction coupled with high–per -formance liquid chromatography for the study of the osthole pharmacokinetics in cerebral ischemia hypoperfusion rat plasma

21 June 2011, 21:42:29Go to full article
Publication year: 2011
Source: Journal of Chromatography B, In Press, Accepted Manuscript, Available online 21 June 2011
Jun, Zhou , Ping, Zeng , Zhao Hui, Cheng , Jing, Liu , Feng Qiao, Wang , ...
A simple and solvent-minimized sample preparation technique based on two-phase hollow fiber liquid phase microextraction has been developed and used to quantify the osthole in cerebral ischemia reperfusion rat plasma following oral administration. The analysis was performed by reversed phase high performance liquid chromatography with fluorescence detection. Extraction conditions such as solvent identity, agitation rate, salt concentration, extraction time, and length of the hollow fiber were optimized. Under the optimized conditions, the linear range of osthole in rat plasma was 5–500ngmL−1 (r2=0.9997). The limit of detection (LOD) was 2ngmL−1 (S/N=3) with limit of quantification (LOQ) being 5ngmL−1. The validated method...

Determination of unbound ticagrelor and its active metabolite (AR-C124910XX) in human plasma by equilibrium dialysis and LC-MS/MS

21 June 2011, 21:42:29Go to full article
Publication year: 2011
Source: Journal of Chromatography B, In Press, Accepted Manuscript, Available online 21 June 2011
Henrik, Sillén , Melanie, Cook , Patty, Davis
Ticagrelor is the first direct acting reversibly binding oral platelet P2Y12 receptor antagonist. The parent molecule and the main metabolite (AR-C124910XX) are both able to block adenosine diphosphate-induced receptor signaling with similar potency. Drug binding to plasma proteins reduces free drug available for pharmacologic activity. Therefore, assessing unbound drug is important for interpretation of pharmacokinetic/pharmacodynamic findings. This paper describes the development and validation of an equilibrium dialysis/LC-MS/MS method for measuring unbound ticagrelor and AR-C124910XX in human plasma. Plasma samples (200μl) were dialysed against phosphate buffered saline (37°C, 24h) in 96-well dialysis plates to separate unbound analytes. Drug-protein binding alterations during...

Therapeutic drug monitoring of tacrolimus by liquid chromatography-tandem mass spectrometry: Is it truly a routine test?

21 June 2011, 21:42:29Go to full article
Publication year: 2011
Source: Journal of Chromatography B, In Press, Accepted Manuscript, Available online 21 June 2011
Paul J., Taylor , Michael E. Franklin Chun-Hui, Tai , Peter I., Pillans
Therapeutic drug monitoring of tacrolimus by high-performance liquid chromatography-tandem mass spectrometry has become standard practice. We report on the long-term (4.5 years) use of one such method. Whole blood samples (25μL) were treated with zinc sulphate (100μL) and acetonitrile containing ascomycin (internal standard, 250μL). A high-performance liquid chromatography-tandem mass spectrometer operating in positive ion mode with an electrospray interface was used. Chromatography was performed on a TDM C18 cartridge column (10×2.1mm, 10μm, Waters) using a switch gradient. A total of 4029 batches were analyzed for tacrolimus; this comprised of 81950 analyses of which 61027 were patient samples. Calibration curves (1.0–50μg/L)...